Towards a blood-based diagnostic panel for bipolar disorder

Brain, Behavior, and Immunity

Volumn 52, Issue , 2016, Pages 49-57

  Haenisch, Frieder ^a   Cooper, Jason D ^a   Reif, Andreas ^b   Kittel Schneider, Sarah ^b   Steiner, Johann ^c   Leweke, F Markus ^d   Rothermundt, Matthias ^e   van Beveren, Nico J M ^f   Crespo Facorro, Benedicto ^g   Niebuhr, David W ^h   Cowan, David N ^h   Weber, Natalya S ^h   Yolken, Robert H ⁱ   Penninx, Brenda W J H ^j   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CANTABRIA   (Spain)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Biomarker; Bipolar disorder; Diagnostic test; Differential diagnosis; Multiplex immunoassay

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIPOLAR DISORDER; BLOOD BASED DIAGNOSTIC PANEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SCORE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL DISEASE ASSESSMENT; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ADULT; BLOOD; CASE CONTROL STUDY; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; MIDDLE AGED;

ADULT; BIOMARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

EID: 84953353664     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.10.001     Document Type: Article

References (43)

1. Ayorech Z., Tracy D.K., Baumeister D., Giaroli G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J. Affect. Disord. 2014, 174C:467-478.
2. Barbosa I.G., Morato I.B., de Miranda A.S., Bauer M.E., Soares J.C., Teixeira A.L. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J. Affect. Disord. 2014, 157:41-44.
3. Bertenshaw G.P., Yip P., Seshaiah P., et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2872-2881.
4. Bilello J.A., Thurmond L.M., Smith K.M., et al. MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J. Clin. Psychiatry 2015, 76:e199-e206.
5. Carta M.G., Moro M.F., Lorefice L., et al. The risk of bipolar disorders in multiple sclerosis. J. Affect. Disord. 2014, 155:255-260.
6. Chan M.K., Gottschalk M.G., Haenisch F., et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog. Neurobiol. 2014, 122C:45-72.
7. Chan M.K., Krebs M.-O., Cox D., et al. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl. Psychiatry 2015, 5:e601.
8. Chopra K., Baveja A., Kuhad A. MMPs: a novel drug target for schizophrenia. Expert Opin. Ther. Targets 2014, 1-9.
9. Clelland C.L., Read L.L., Panek L.J., Nadrich R.H., Bancroft C., Clelland J.D. Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile. PLoS ONE 2013, 8. 10.1371/journal.pone.0069082.
10. Colom F., Vieta E., Daban C., Pacchiarotti I., Sánchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J. Affect. Disord. 2006, 93:13-17.
11. Cossins J.A., Clements J.M., Ford J., et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 1997, 94:590-598.
12. Friedman J., Hastie T., Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 2010, 33:1-22.
13. Ghaemi S.N., Sachs G.S., Chiou A.M., Pandurangi A.K., Goodwin F.K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?. J. Affect. Disord. 1999, 52:135-144.
14. James Gareth, Witten Daniela, Hastie Trevor, Tibshirani Robert An Introduction to Statistical Learning: With Applications in R, Corr. 4th 2013, Springer.
15. Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127.
16. Kaplan I., Bulut M., Atli A., Güneş M., Kaya M.C., Çolpan L. Serum levels of carcinoembryonic antigen (CEA) in patients with bipolar disorder. Acta Neuropsychiatr. 2015, 27:177-181.
17. Keeney J.T.R., Swomley A.M., Förster S., Harris J.L., Sultana R., Butterfield D.A. Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Proteomics Clin. Appl. 2013, 7:109-122.
18. Kim Y.-K., Jung H.-G., Myint A.-M., Kim H., Park S.-H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104:91-95.
19. Knijff E.M., Nadine B.M., Kupka R.W., et al. An imbalance in the production of IL-1β and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007, 9:743-753.
20. Kupka R.W., Breunis M.N., Knijff E., Ruwhof C., Nolen W.A., Drexhage H.A. Immune activation, steroid resistancy and bipolar disorder. Bipolar Disord. 2002, 4(Suppl. 1):73-74.
21. Lakka H.-M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
22. Leek J.T., Johnson W.E., Parker H.S., Jaffe A.E., Storey J.D. The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012, 28:882-883.
23. Le-Niculescu H., Kurian S.M., Yehyawi N., et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol. Psychiatry 2009, 14:156-174.
24. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 1995, 154:4379-4389.
25. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 1996, 55:300-309.
26. Merikangas K.R., Akiskal H.S., Angst J., et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 2007, 64:543-552.
27. Niebuhr D.W., Millikan A.M., Yolken R., Li Y., Weber N.S. Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel. Schizophr. Bull. 2008, 34:1182-1188.
28. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90:263-267.
29. Padmos R.C., Hillegers M.H.J., Knijff E.M., et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65:395-407.
30. Papakostas G.I., Shelton R.C., Kinrys G., et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry 2013, 18:332-339.
31. Penninx B.W.J.H., Beekman A.T.F., Smit J.H., et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int. J. Methods Psychiatr. Res. 2008, 17:121-140.
32. Perdue C.L., Cost A.A.E., Rubertone M.V., Lindler L.E., Ludwig S.L. Description and utilization of the United States department of defense serum repository: a review of published studies, 1985-2012. PLoS ONE 2015, 10:e0114857.
33. R Core Team, 2014. R: A Language and Environment for Statistical Computing.
34. Romi F., Helgeland G., Gilhus N.E. Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur. Neurol. 2012, 67:121-128.
35. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 1992, 576:203-207.
36. Rosenblat J.D., McIntyre R.S. Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. Acta Psychiatr. Scand. 2015, 10.1111/acps.12414.
37. Rubertone M.V., Brundage J.F. The Defense Medical Surveillance System and the Department of Defense Serum Repository: glimpses of the future of public health surveillance. Am. J. Public Health 2002, 92:1900-1904.
38. Schwarz E., Guest P.C., Rahmoune H., et al. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J. Biol. Psychiatry 2011, 10.3109/15622975.2011.599861.
39. Schwarz E., Guest P.C., Rahmoune H., et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, published online April. 10.1038/mp.2011.42.
40. Thomas P., Forse R.A., Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin. Exp. Metastasis 2011, 28:923-932.
41. Vieta E., Berk M., Wang W., Colom F., Tohen M., Baldessarini R.J. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J. Affect. Disord. 2009, 119:22-27.
42. Waubant E., Goodkin D.E., Gee L., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999, 53:1397-1401.
43. Zetterberg H., Jakobsson J., Redsäter M., et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. 2014, 217:143-146.